NDUFA10

NDUFA10 is an accessory/assembly subunit of mitochondrial respiratory complex I required for complex I integrity and electron transfer, and through it for ATP synthesis and mitochondrial membrane potential (PMID:24652937, PMID:21150889). Compound-heterozygous loss-of-function mutations in NDUFA10 reduce complex I amount, activity, and assembly in patient cells, establishing it as a structural subunit needed for complex I assembly (PMID:21150889). Its activity is gated by regulated phosphorylation: PINK1 phosphorylates serine-250 of NDUFA10, an event required for ubiquinone reduction by complex I, such that loss of PINK1 abolishes this phosphorylation and produces complex I reductive deficiency, membrane depolarization, and synaptic defects that a phosphomimetic NDUFA10 rescues across mouse and Drosophila models (PMID:24652937). This PINK1–NDUFA10 axis acts independently of mitophagy, rescuing pink1 but not parkin mutant phenotypes (PMID:25412178). Beyond its complex I role, NDUFA10 carries a deoxyribonucleoside kinase (dNK) domain that directly binds dGTP and sequesters the majority of the mitochondrial dGTP pool, a function separable from complex I assembly and activity (PMID:35739187). NDUFA10 stability and complex I output are further modulated by physical partners including CAV3, which limits its lysosomal degradation (PMID:38671439), neuroglobin (PMID:39454716), and β-arrestin2 recruited downstream of the dopamine D2 receptor (PMID:42174197). In neural tissue, NDUFA10-dependent complex I activity sets cortical ATP availability and thereby influences anesthesia sensitivity (PMID:40415484).

1. 2005 High

   Before functional regulation was known, it was unclear whether NDUFA10 was post-translationally modified; mapping a phosphosite established that the subunit is a substrate for regulatory modification within complex I.

   Evidence MS/MS of bovine heart mitochondrial complex I with synthetic peptide confirmation identifying phospho-serine-59

   PMID:15848193

   Open questions at the time

   • No kinase identified for this site
   • Functional consequence of the phosphorylation not tested
2. 2008 Medium

   Extending the modification inventory, broad PTM and variant mapping showed NDUFA10 carries numerous methylations, acetylations, and reactive residues, framing it as a heavily modified subunit.

   Evidence 2-DE plus MS/MS of rat brain mitochondrial complex I mapping 33 PTMs at 59 residues and a D120N variant

   PMID:18442173

   Open questions at the time

   • Functional significance of individual modifications not validated
   • No link to complex I activity established
3. 2010 Medium

   It was unknown whether NDUFA10 is essential for complex I; patient mutations demonstrated it is a structural/assembly subunit required for complex I integrity and a cause of mitochondrial disease.

   Evidence Genetic screening of patient fibroblasts/muscle with BN-PAGE assembly and activity assays of compound-heterozygous mutations

   PMID:21150889

   Open questions at the time

   • No mutagenesis reconstitution to prove causality
   • Assembly intermediate accumulation not resolved
   • Single lab, limited patient number
4. 2014 High

   The mechanism connecting PINK1 to bioenergetics was unknown; phosphorylation of NDUFA10 serine-250 by PINK1 was shown to be required for ubiquinone reduction, linking PINK1 kinase activity directly to complex I electron transfer.

   Evidence Phosphoproteomics of Pink1(-/-) mouse tissue plus phosphomimetic mutagenesis and rescue in mouse KO cells and Drosophila pink1 nulls

   PMID:24652937

   Open questions at the time

   • Direct in vitro kinase assay on isolated NDUFA10 not shown
   • Structural basis of how S250 phosphorylation enables Q reduction unresolved
5. 2014 High

   Whether the PINK1–NDUFA10 axis operated through mitophagy was open; genetic epistasis established the rescue is mitophagy-independent and specific to PINK1-dependent complex I regulation.

   Evidence Transgenic ND42/sicily overexpression in Drosophila pink1 vs parkin mutants, human cell knockdown, and CCCP mitophagy/Parkin translocation assays

   PMID:25412178

   Open questions at the time

   • Mechanism distinguishing PINK1 substrate selection from Parkin pathway unresolved
   • Co-chaperone sicily contribution to human NDUFA10 not defined
6. 2022 High

   The function of NDUFA10's dNK domain was unknown; it was shown to directly bind and sequester most of the mitochondrial dGTP pool, a moonlighting role separable from complex I assembly.

   Evidence dNK domain mutagenesis (E160A/R161A) in HEK-293T, in vitro dGTP binding, and mitochondrial dNTP pool measurements

   PMID:35739187

   Open questions at the time

   • Physiological consequence of dGTP sequestration not established
   • Whether dGTP binding feeds back on complex I function untested
7. 2024 Medium

   Regulators controlling NDUFA10 abundance were unknown; CAV3 was identified as a direct partner that limits lysosomal degradation of NDUFA10 to preserve complex I activity in diabetic cardiomyopathy.

   Evidence LC-MS/MS interactome, reciprocal co-IP, and CAV3 cardiac overexpression in db/db mice with complex I activity assays

   PMID:38671439

   Open questions at the time

   • Degradation machinery routing NDUFA10 to lysosomes not defined
   • Single lab
8. 2024 Medium

   Whether neuroglobin acts on complex I via NDUFA10 was unknown; co-IP and functional rescue placed Ngb as an NDUFA10 partner supporting complex I activity in a Parkinson's cell model.

   Evidence Co-IP in MN9D cells plus complex I activity, membrane potential, NAD+/NADH, ROS, and apoptosis readouts with Ngb knockdown/overexpression

   PMID:39454716

   Open questions at the time

   • Single co-IP without reciprocal validation in this context
   • Direct vs indirect interaction not resolved
9. 2026 Medium

   The downstream effector of astrocytic dopamine D2 receptor neuroprotection was unclear; β-arrestin2 was shown to bridge Drd2 signaling to NDUFA10, with NDUFA10 knockdown abolishing the neuroprotective effect.

   Evidence Transcriptomics, metabolomics, β-arrestin2 co-IP with NDUFA4/NDUFA10, and astrocyte-selective NDUFA10 knockdown in a mouse PD model

   PMID:42174197

   Open questions at the time

   • Whether β-arrestin2 alters NDUFA10 phosphorylation or stability unknown
   • Single lab
10. 2025 Medium

    Whether NDUFA10 sets tissue-level energy state was untested; site-specific knockdown showed NDUFA10-dependent complex I activity is upstream of cortical ATP availability and anesthesia sensitivity.

    Evidence Stereotaxic viral knockdown in mouse mPFC with in vivo ATP monitoring, EEG burst suppression, and ATP rescue

    PMID:40415484

    Open questions at the time

    • Cell-type specificity of the effect not fully resolved
    • Link to PINK1 phosphorylation in this context not tested

• It remains unresolved how the multiple regulatory inputs (PINK1 phosphorylation, dGTP sequestration, CAV3/Ngb/β-arrestin2 partners) are integrated to set complex I output, and whether they act through shared or independent mechanisms.
• No structural model of S250 phosphorylation effect on complex I
• Physiological role of dGTP sequestration unknown
• Cross-talk among the named partners untested